KyungMann Kim

ORCID: 0000-0002-6726-003X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Statistical Methods in Clinical Trials
  • Cancer Immunotherapy and Biomarkers
  • Cutaneous Melanoma Detection and Management
  • Neuroblastoma Research and Treatments
  • Statistical Methods and Inference
  • Lung Cancer Treatments and Mutations
  • Statistical Methods and Bayesian Inference
  • Optimal Experimental Design Methods
  • Lymphoma Diagnosis and Treatment
  • Health Systems, Economic Evaluations, Quality of Life
  • Cancer therapeutics and mechanisms
  • Immune Cell Function and Interaction
  • Estrogen and related hormone effects
  • Multiple Myeloma Research and Treatments
  • Cancer Treatment and Pharmacology
  • Advanced Causal Inference Techniques
  • Lung Cancer Research Studies
  • Inflammatory mediators and NSAID effects
  • Prostate Cancer Treatment and Research
  • Monoclonal and Polyclonal Antibodies Research
  • Bladder and Urothelial Cancer Treatments
  • Retinoids in leukemia and cellular processes
  • Chronic Lymphocytic Leukemia Research

University of Wisconsin–Madison
2016-2025

University of Wisconsin Carbone Cancer Center
2014-2024

The University of Texas Southwestern Medical Center
2023

Southwestern Medical Center
2023

Statistical Service
2023

Wisconsin Alumni Research Foundation
2021

Madison Group (United States)
2015-2016

Johns Hopkins University
2012

National Cancer Institute
2010-2012

University of Iowa
2012

For small-cell lung cancer confined to one hemithorax (limited cancer), thoracic radiotherapy improves survival, but the best ways of integrating chemotherapy and remain unsettled. Twice-daily accelerated has potential advantages over once-daily radiotherapy.

10.1056/nejm199901283400403 article EN New England Journal of Medicine 1999-01-28

10.1016/s0197-2456(00)00127-6 article EN Controlled Clinical Trials 2001-02-01

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine whether new agent, paclitaxel, would further improve NSCLC, the Eastern Cooperative Oncology Group conducted randomized trial comparing paclitaxel plus cisplatin to standard regimen consisting of and etoposide. PATIENTS AND METHODS: The study was carried out by multi-institutional cooperative group chemotherapy-naive...

10.1200/jco.2000.18.3.623 article EN Journal of Clinical Oncology 2000-02-01

Abstract Moment methods for analysing repeated binary responses have been proposed by Liang and Zeger, extended Prentice Zhao Prentice. In these estimating equations, models are the correlation between responses. We extend Zeger's method to nominal or ordinal categorical responses; in particular, when binary, our reduce method. Our is illustrated with two datasets. One dataset contains observations of self‐assessment arthritis, an ordered variable three categories, collected during a...

10.1002/sim.4780131106 article EN Statistics in Medicine 1994-06-15

Neoantigens induced by random mutations and specific to an individual's cancer are the most important tumor antigens recognized T cells. Among immunologically "cold" tumors, limited recognition of neoantigens results in absence a de novo antitumor immune response. These tumors present clinical challenge as they poorly responsive immunotherapies, including checkpoint inhibitors (ICIs). Radiation therapy (RT) can enhance resulting more diversified T-cell response, yet RT alone rarely systemic...

10.1002/adma.201902626 article EN publisher-specific-oa Advanced Materials 2019-09-16

PURPOSE The purpose of this study was to evaluate the impact cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma respect response rate, duration remission, overall survival. PATIENTS AND METHODS Assessable (n = 29) or thymic carcinoma 1) metastatic locally progressive recurrent disease following radiotherapy were treated intravenous cisplatin (50 mg/m2), doxorubicin (500 mg/m2) normal saline hydration. Courses repeated every 3 weeks for a maximum eight cycles...

10.1200/jco.1994.12.6.1164 article EN Journal of Clinical Oncology 1994-06-01

SUMMARY Lan & DeMets (1983) devised a method of constructing discrete group sequential boundaries by using the type I error spending rate function. It is extended so as to generate asymmetric well symmetric two-sided for clinical trials. The design aspect this procedure explored in terms maximum sample size needed achieve desired level power and expected stopping times under both null alternative hypotheses. Finally, these properties are employed search appropriate functions differing situations.

10.1093/biomet/74.1.149 article EN Biometrika 1987-01-01

PURPOSE To determine the response rate of cisplatin plus doxorubicin cyclophosphamide (PAC) in patients with limited-stage unresectable thymoma. In addition, this study was undertaken to toxicity, progression-free survival, and overall survival combined-modality therapy PAC radiation therapy. PATIENTS AND METHODS Patients a histologic diagnosis thymoma or thymic carcinoma were eligible. Further requirements included Karnofsky Performance Score > 60, no prior chest, adequate bone marrow,...

10.1200/jco.1997.15.9.3093 article EN Journal of Clinical Oncology 1997-09-01

To compare the validity of various physical activity measures with doubly labeled water (DLW)-measured energy expenditure (PAEE) in free-living older adults.Fifty-six adults aged ≥65 yr wore three monitors (New Lifestyles pedometer, ActiGraph accelerometer, and a SenseWear (SW) armband) during 10-d period completed different surveys (Yale Physical Activity Survey (YPAS), Community Health Activities Model Program for Seniors (CHAMPS), modified Scale Elderly (modPASE)). Total was measured...

10.1249/mss.0b013e3181fc7162 article EN Medicine & Science in Sports & Exercise 2010-09-29

Abstract The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk cancer. trial randomized 2,035 subjects to receive either placebo, celecoxib 200 mg twice daily, or 400 daily. primary study analyses involved 3 years treatment. results showed significant antitumor effect but also indicated increased cardiovascular adverse events treated compared placebo. A...

10.1158/1940-6207.capr-08-0206 article EN Cancer Prevention Research 2009-03-31

To develop novel mechanism-based preventive approaches for lung cancer, we examined the effect of oral consumption a human achievable dose pomegranate fruit extract (PFE) on growth, progression, angiogenesis, and signaling pathways in two mouse tumor protocols. Benzo(a)pyrene [B(a)P] N-nitroso-tris-chloroethylurea (NTCU) were used to induce tumors, PFE was given drinking water A/J mice. Lung yield 84th day 140 days after B(a)P dosing 240 NTCU treatment. Mice treated with exposed had...

10.1158/0008-5472.can-06-3941 article EN Cancer Research 2007-03-28

<h3>Importance</h3> Influenza is temporally associated with cardiopulmonary morbidity and mortality among those cardiovascular disease who may mount a less vigorous immune response to vaccination. Higher influenza vaccine dose has been reduced risk of illness. <h3>Objective</h3> To evaluate whether high-dose trivalent compared standard-dose quadrivalent would reduce all-cause death or hospitalization in high-risk patients disease. <h3>Design, Setting, Participants</h3> Pragmatic multicenter,...

10.1001/jama.2020.23649 article EN JAMA 2020-12-05

High food insecurity has been demonstrated in rural American Indian households, but little is known about families urban settings or the association of with diet for these families. The purpose this study was to examine prevalence households by urban-rural status, correlates and relationship between households. Dyads consisting an adult caregiver a child (2–5 years old) from same household five communities were included. Demographic information collected, assessed using two validated items...

10.1186/s12889-017-4498-y article EN cc-by BMC Public Health 2017-06-30

Abstract Radiation therapy (RT) activates an in situ vaccine effect when combined with immune checkpoint blockade (ICB), yet this may be limited because RT does not fully optimize tumor antigen presentation or overcome suppressive mechanisms the tumor-immune microenvironment. To this, we develop a multifunctional nanoparticle composed of polylysine, iron oxide, and CpG (PIC) to increase presentation, ratio M1:M2 tumor-associated macrophages, enhance stimulation type I interferon response...

10.1038/s41467-022-32645-x article EN cc-by Nature Communications 2022-08-23

Abstract In a typical two‐stage design for phase II cancer clinical trial efficacy screening of cytotoxic agents, fixed number patients are initially enrolled and treated. The may be terminated lack if the observed tumour responses after first stage is too small, thus avoiding treatment patient with inefficacious regimen. Otherwise, an additional treated to accumulate information on as well safety. minimax so‐called ‘optimal’ designs by Simon have been widely used, other largely ignored in...

10.1002/sim.1600 article EN Statistics in Medicine 2004-01-23

Abstract Bortezomib (Velcade/PS341), a proteasome inhibitor used in the treatment of multiple myeloma (MM), can inhibit activation nuclear factor-κB (NF-κB), family transcription factors often deregulated and constitutively activated primary MM cells. NF-κB be via several distinct mechanisms, including inhibitor–resistant (PIR) pathway. It remains unknown what fraction cells harbor constitutive activity maintained by proteasome-dependent mechanisms. Here, we report an unexpected finding that...

10.1158/1541-7786.mcr-08-0108 article EN Molecular Cancer Research 2008-08-01

Abstract Preclinical studies have shown that the inhibition of ornithine decarboxylase (ODC) by α-difluoromethylornithine (DFMO) and resultant decreases in tissue concentrations polyamines (putrescine spermidine) prevents neoplastic developments many types. Clinical oral DFMO at 500 mg/m2/day revealed it to be safe tolerable resulted significant phorbol ester–induced skin ODC activity. Two hundred ninety-one participants (mean age, 61 years; 60% male) with a history prior nonmelanoma cancer...

10.1158/1940-6207.capr-09-0096 article EN Cancer Prevention Research 2010-01-01

The soy compound genistein has been observed preclinically to inhibit bladder cancer growth with one potential mechanism being the inhibition of epidermal factor receptor phosphorylation (p-EGFR). A phase 2 randomized, placebo-controlled trial investigated whether daily, oral (300 or 600 mg/d as purified extract G-2535) for 14 21 days before surgery alters molecular pathways in epithelial tissue 59 subjects diagnosed urothelial (median age, 71 years). G-2535 treatment was well tolerated;...

10.1158/1940-6207.capr-11-0455 article EN Cancer Prevention Research 2012-02-01

Abstract We performed a phase II pharmacodynamic prevention trial of Polyphenon E [a green tea polyphenol formulation primarily consisting epigallocatechin gallate (EGCG)] in patients prior to bladder cancer surgery. Patients with tumor were randomized receive containing either 800 or 1,200 mg EGCG placebo for 14 28 days transurethral resection cystectomy. The primary objective was compare the postintervention tissue levels receiving as compared placebo. Secondary objectives included...

10.1158/1940-6207.capr-16-0167 article EN Cancer Prevention Research 2017-03-22
Coming Soon ...